Meeting
2022 ASCO Gastrointestinal Cancers Symposium
CSF-1R inhibitor, pexidartinib, sensitizes esophageal cancer to PD-1 immune checkpoint blockade in a rat model.
Authors
Michael Paskewicz
Esophageal and Lung Research, Allegheny Health Network, Pittsburgh, PA
Michael Paskewicz , Ashten Omstead , Ping Zheng , Anastasia Gorbunova , Madison Salvitti , Adam Alleyne , Payton Reed , Sydne Ballengee , Nabeela Islam , Blair A. Jobe , Ronan Joseph Kelly , Ali Hussainy Zaidi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.333
Abstract #
333
Poster Bd #
G9
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.
First Author: John H. Strickler
Poster
2023 ASCO Annual Meeting
Effects of yoga vs placebo on inflammation among cancer survivors: A nationwide multicenter phase III randomized controlled trial (RCT).
First Author: Po-Ju Lin
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy.
First Author: Sean Mackay